Information for Patients
PRECISION MEDICINE FOR CANCER PATIENTS
No two cancers—and no two patients—are the same. If you or a loved one is facing cancer you deserve care that takes the unique biology of your tumor into account.
The Cure-First team has experience with many types of solid tumors including Pancreatic, Breast, Ovarian, Prostate, Colon, Gastric, Small Bowel, Liver and Biliary Tract, Lung, Head and Neck Cancer, Sarcomas, Glioblastoma, other Brain cancers, Rare Cancers, Metastatic cancers and more.
The PARIS® Test from Cure First is designed to help your care team identify treatment options tailored specifically to your cancer. By testing dozens of therapies directly on your own cancer cells and combining those results with advanced genomic analysis, the PARIS® Test helps uncover vulnerabilities that may not be revealed through standard testing alone.
Cure First’s goal is to provide your oncologist with actionable information that can support more informed treatment decisions, particularly when standard options are limited or uncertain. Cure First is dedicated to making functional precision medicine accessible to cancer patients.
To learn more, or for information for your doctor, please contact our clinical team at ParisTest@cure-first.org
How the PARIS® Test Works
The PARIS® Test is a functional drug sensitivity screening test performed on a sample of your own tumor tissue, typically collected during a biopsy, surgery or from fluid buildup.
The live tumor or fluid sample is sent to Cure First’s CLIA-certified laboratory where they are expanded into live 3D tumor models. Those models are then exposed to a personalized menu of up to 47 cancer drugs, including targeted therapies (both small molecule drugs and antibody drug-conjugates) as well as chemotherapies, selected based on your tumor’s genetic vulnerabilities. Using high-throughput robotic testing and a bioinformatics pipeline, a specialized team of scientists at Cure First evaluates how your cancer cells respond to each treatment option. These results can be used alongside your DNA sequencing results. Your care provider receives a custom report that ranks potential therapies based on their activity against your live tumor cells.
Personalized: We are testing the drugs on your very own cancer cells.
Aimed: We find the Achilles’ heel specific to your cancer.
Robotic testing allows us to rapidly test hundreds of drugs.
Informatics: The large amount of data derived from your tumor is analyzed and carefully prepared for your oncologist.
Sequenced: Deep DNA sequencing helps determine which mutations are driving a patient’s cancer and should be targeted.
WHY THE PARIS® Test IS IMPORTANT FOR YOUR CARE
It’s better than DNA sequencing alone. While DNA sequencing may indicate an actionable potential treatment in ~20% of cases; the PARIS® Test has shown >90% actionability.
Conducting the PARIS® Test before starting your treatment can guide you directly to the most effective options for your specific tumor; avoiding other treatments that may be less effective or cause unnecessary side effects.
If your cancer has recurred after treatment, or progressed during treatment, the PARIS® Test allows you to be prepared for a possible second line treatment - a plan B option.
If your cancer is rare, metastatic, or at high-risk of recurrence the PARIS® Test can provide more options for you and your oncologist to consider.
What Happens After Results Are Available
Your oncologist receives a comprehensive clinical report in approximately 3–4 weeks. A member of our scientific team is available to review the findings with your provider and can participate in molecular tumor boards for complex cases.
The PARIS® Test is intended to complement next-generation sequencing (NGS) and other diagnostic tools to help you and your oncologist identify treatment options.
The therapies evaluated in the PARIS® Test may include drugs approved for the cancer being tested as well as those currently approved for other cancers (off-label use), or actively being studied in clinical trials. In some cases, the PARIS® Test results may help your oncologist identify relevant clinical trials that are enrolling patients and may be appropriate to consider.
While the PARIS® Test can help inform treatment decisions, it does not guarantee a specific outcome or response.
To learn more, or for information for your doctor, please visit our How to Order page or contact us at ParisTest@cure-first.org to speak with our clinical coordinators and complete the patient pre-screen.
case reports: the real-world impact of the PARIS® Test
How to Advocate for
Functional Testing
Personalized cancer testing is an evolving field, and not every oncologist may be familiar with the PARIS® Test. If you have a solid tumor and are exploring additional options, you can ask your oncologist to contact us to learn more about whether the PARIS® Test may be appropriate for you.
Many patients and their medical teams pursue the PARIS® Test to gain additional insight, confidence, and clarity—especially when facing difficult treatment decisions or limited treatment options. By providing deeper information about how your individual cancer responds to therapy, the PARIS® Test may help support conversations that align treatment choices with your unique cancer and your goals of care.